DuPont Announces Agreement to Divest Aramids Business to Arclin

• Transaction structure maximizes shareholder value, enables participation in future upside potential of combined new entity
• Divestiture further streamlines the new DuPont portfolio and improves its financial profile

WILMINGTON, Del., Aug. 29, 2025 – DuPont (NYSE: DD) today announced that Arclin, a portfolio company of an affiliate of TJC, L.P. (TJC), has reached a definitive agreement to acquire DuPont’s Aramids business (Kevlar^® and Nomex^®) in a transaction valuing the business at approximately $1.8 billion.

Arclin has received fully committed financing in connection with the transaction, which is expected to close in the first quarter of 2026, subject to customary closing conditions and regulatory approval.

At close, DuPont will receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in the future Arclin company currently valued at $325 million, which is expected to represent an approximate 17.5% stake at the time of close.

“Today’s announcement is another important step in our continued optimization of the new DuPont portfolio,” said Lori Koch, DuPont Chief Executive Officer. “The Aramids transaction further enhances the strategic focus of our portfolio, while also increasing the growth and margin profile. The transaction is structured to maximize value for our shareholders by providing significant cash proceeds at close which will be re-deployed to further drive value creation, while also allowing DuPont shareholders to participate in Arclin’s growth potential through our retained equity interest,” continued Koch.

“We are excited to partner again with TJC given their successful track record of creating value through an operations-focused approach and are confident in their ability to drive growth and opportunity for the employees and customers of the combined businesses,” Koch concluded.

“The addition of Kevlar^® and Nomex^® to the Arclin portfolio presents a unique opportunity to transform our business with increased scale, broader global reach, and market-leading application development capabilities. The growth potential this acquisition presents will allow us to double down on our commitment to bringing impactful solutions and products to market, such as Arclin Firepoint, that protect what matters most,” said Bradley Bolduc, Arclin’s President and Chief Executive Officer. “We are excited about the endless opportunities ahead of us with these businesses in our portfolio.”

The Aramids business is the inventor and largest global producer of industry-leading high performance synthetic fibers that protect people, equipment and structures in high cost-of-failure applications. Aramids’ synthetic fibers, Kevlar^® and Nomex^®, are well-known brands globally with a longstanding reputation for quality, product performance and supply reliability. With about 1,900 employees and five manufacturing sites, the Aramids business generated net sales of $1.3 billion in 2024.

The Aramids divestiture will not impact DuPont’s intended separation of its electronics business (Qnity), which remains on track for a November 1, 2025 spin-off.

Centerview Partners and Goldman Sachs & Co. LLC and are serving as DuPont’s financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel. Piper Sandler & Company is serving as financial advisor and Kirkland & Ellis LLP is serving as legal counsel to TJC/Arclin.